Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.

Item

http://www.wikidata.org/entity/Q35854094

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.

@ast

Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.

@en

type

Item

label

Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.

@ast

Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.

@en

prefLabel

Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.

@ast

Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.

@en

P1476

Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.

@en

P2093

Aaron T Gerds

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.

Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematol

P304

71-75

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MOH.0B013E32834FF562

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hans Joachim Deeg

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221731435

http://www.w3.org/2001/XMLSchema#string

P698

22227527

http://www.w3.org/2001/XMLSchema#string

P932

3312783

http://www.w3.org/2001/XMLSchema#string